-
Je něco špatně v tomto záznamu ?
Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation
F Duska, M Fric, P Waldauf, J Pazout, M Andel, P Mokrejs, P Tuma, J Pachl
Jazyk angličtina Země Spojené státy americké
Typ dokumentu srovnávací studie, randomizované kontrolované studie
Grantová podpora
NR8230
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
NLK
Journals@Ovid Ovid Full Text
od 2000-01-01 do 2010-02-01
- MeSH
- amoniak moč MeSH
- APACHE MeSH
- délka pobytu MeSH
- dipeptidy aplikace a dávkování MeSH
- dospělí MeSH
- dusík moč MeSH
- dvojitá slepá metoda MeSH
- energetický metabolismus účinky léků MeSH
- financování organizované MeSH
- index tělesné hmotnosti MeSH
- intravenózní infuze MeSH
- inzulinová rezistence fyziologie MeSH
- kombinovaná farmakoterapie MeSH
- kreatinin moč MeSH
- krevní glukóza metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidský růstový hormon aplikace a dávkování MeSH
- míra přežití MeSH
- nepřímá kalorimetrie MeSH
- péče o pacienty v kritickém stavu metody MeSH
- pilotní projekty MeSH
- polytrauma farmakoterapie mortalita patofyziologie MeSH
- prospektivní studie MeSH
- pulzní dávkování léků MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- randomizované kontrolované studie MeSH
- srovnávací studie MeSH
OBJECTIVES: To estimate the efficacy and metabolic effects of growth hormone substitution as intravenous pulses together with alanyl-glutamine supplementation and tight blood glucose control in prolonged critical illness. DESIGN: Prospective double-blind, randomized trial with open-label control arm. SETTING: Intensive care unit of tertiary level hospital. PATIENTS: Thirty multiple trauma patients (median Injury Severity Score 34). INTERVENTIONS: Patients were randomized, at day 4 after trauma, to receive intravenous alanyl-glutamine supplementation (0.3 g/kg x day(-1) from day 4 until day 17) and intravenous growth hormone (administered days 7-17, full dose 50 microg/kg x day(-1) from day 10 onward) (group 1, n = 10) or alanyl-glutamine and placebo (group 2, n = 10). Group 3 (n = 10) received isocaloric isonitrogenous nutrition (proteins 1.5 g/kg x day(-1)) without alanyl-glutamine. MEASUREMENTS AND MAIN RESULTS: Cumulative nitrogen balance for the whole study period was -97 +/- 38 g of nitrogen for group 1, -193 +/- 50 g of nitrogen for group 2, and -198 +/- 77 g of nitrogen for group 3 (p < .001). This represents a daily saving of 300 g of lean body mass in group 1. Insulin-mediated glucose disposal, during euglycemic clamp, as a measure of insulin sensitivity, significantly worsened between days 4 and 17 in group 1 but improved in groups 2 and 3. Group 1 required significantly more insulin to control blood glucose, resulting in higher insulinemia (approximately 70 mIU in group 1 vs. approximately 25 mIU in groups 2 and 3). Despite this, growth hormone treatment caused an increase in plasma nonesterified fatty acid (approximately 0.5-0.6 mM in group 1 in comparison with approximately 0.2-0.3 mM in groups 2 and 3) but did not influence lipid oxidation. There were no differences in morbidity, mortality, or 6-month outcome among the groups. CONCLUSIONS: Treatment with frequent intravenous pulses of low-dose growth hormone together with alanyl-glutamine supplementation improves nitrogen economy in patients with prolonged critical illness after multiple trauma but worsens insulin sensitivity. Tight blood glucose control is possible but requires higher doses of insulin.
Citace poskytuje Crossref.org
- 000
- 02535naa 2200625 a 4500
- 001
- bmc11002936
- 003
- CZ-PrNML
- 005
- 20131002105432.0
- 008
- 110225s2008 xxu e eng||
- 009
- AR
- 024 __
- $a 10.1097/ccm.0b013e318174d499 $2 doi
- 035 __
- $a (PubMed)18496372
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Duška, František, $d 1976- $7 mzk2007386027
- 245 10
- $a Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation / $c F Duska, M Fric, P Waldauf, J Pazout, M Andel, P Mokrejs, P Tuma, J Pachl
- 314 __
- $a Department of Anesthesia and Critical Care Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic, EU. fduska@yahoo.com
- 520 9_
- $a OBJECTIVES: To estimate the efficacy and metabolic effects of growth hormone substitution as intravenous pulses together with alanyl-glutamine supplementation and tight blood glucose control in prolonged critical illness. DESIGN: Prospective double-blind, randomized trial with open-label control arm. SETTING: Intensive care unit of tertiary level hospital. PATIENTS: Thirty multiple trauma patients (median Injury Severity Score 34). INTERVENTIONS: Patients were randomized, at day 4 after trauma, to receive intravenous alanyl-glutamine supplementation (0.3 g/kg x day(-1) from day 4 until day 17) and intravenous growth hormone (administered days 7-17, full dose 50 microg/kg x day(-1) from day 10 onward) (group 1, n = 10) or alanyl-glutamine and placebo (group 2, n = 10). Group 3 (n = 10) received isocaloric isonitrogenous nutrition (proteins 1.5 g/kg x day(-1)) without alanyl-glutamine. MEASUREMENTS AND MAIN RESULTS: Cumulative nitrogen balance for the whole study period was -97 +/- 38 g of nitrogen for group 1, -193 +/- 50 g of nitrogen for group 2, and -198 +/- 77 g of nitrogen for group 3 (p < .001). This represents a daily saving of 300 g of lean body mass in group 1. Insulin-mediated glucose disposal, during euglycemic clamp, as a measure of insulin sensitivity, significantly worsened between days 4 and 17 in group 1 but improved in groups 2 and 3. Group 1 required significantly more insulin to control blood glucose, resulting in higher insulinemia (approximately 70 mIU in group 1 vs. approximately 25 mIU in groups 2 and 3). Despite this, growth hormone treatment caused an increase in plasma nonesterified fatty acid (approximately 0.5-0.6 mM in group 1 in comparison with approximately 0.2-0.3 mM in groups 2 and 3) but did not influence lipid oxidation. There were no differences in morbidity, mortality, or 6-month outcome among the groups. CONCLUSIONS: Treatment with frequent intravenous pulses of low-dose growth hormone together with alanyl-glutamine supplementation improves nitrogen economy in patients with prolonged critical illness after multiple trauma but worsens insulin sensitivity. Tight blood glucose control is possible but requires higher doses of insulin.
- 650 _2
- $a APACHE $7 D018806
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a amoniak $x moč $7 D000641
- 650 _2
- $a krevní glukóza $x metabolismus $7 D001786
- 650 _2
- $a index tělesné hmotnosti $7 D015992
- 650 _2
- $a nepřímá kalorimetrie $7 D002153
- 650 _2
- $a kreatinin $x moč $7 D003404
- 650 _2
- $a péče o pacienty v kritickém stavu $x metody $7 D003422
- 650 _2
- $a dipeptidy $x aplikace a dávkování $7 D004151
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a energetický metabolismus $x účinky léků $7 D004734
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidský růstový hormon $x aplikace a dávkování $7 D019382
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intravenózní infuze $7 D007262
- 650 _2
- $a inzulinová rezistence $x fyziologie $7 D007333
- 650 _2
- $a délka pobytu $7 D007902
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a polytrauma $x farmakoterapie $x mortalita $x patofyziologie $7 D009104
- 650 _2
- $a dusík $x moč $7 D009584
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a pulzní dávkování léků $7 D020551
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a financování organizované $7 D005381
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Fric, Michal. $7 xx0241106
- 700 1_
- $a Waldauf, Petr $7 xx0085547
- 700 1_
- $a Pažout, Jaroslav $7 xx0137181
- 700 1_
- $a Anděl, Michal, $d 1946- $7 jn19981228006
- 700 1_
- $a Mokrejš, Pavel. $7 _AN054765
- 700 1_
- $a Tůma, Petr $7 xx0105786
- 700 1_
- $a Pachl, Jan, $d 1949- $7 nlk19990073644
- 773 0_
- $t Critical Care Medicine $w MED00009514 $g Roč. 36, č. 6 (2008), s. 1707-1713
- 910 __
- $a ABA008 $b x $y 1
- 990 __
- $a 20110413123548 $b ABA008
- 991 __
- $a 20131002105949 $b ABA008
- 999 __
- $a ok $b bmc $g 830353 $s 694924
- BAS __
- $a 3
- BMC __
- $a 2008 $b 36 $c 6 $d 1707-1713 $m Critical care medicine $n Crit Care Med $x MED00009514
- GRA __
- $a NR8230 $p MZ0
- LZP __
- $a 2011-2B/dkme